Skip to content

News

Ovarian Cancer Research Fund Awards a Record-Breaking $6.9 ...

Ovarian Cancer Research Fund Awards a Record-Breaking $6.9 Million in Grants

Kicks off 20th Anniversary with an unprecedented grant award for scientific research and gynecologic cancer patient support program New York, NY January 13, 2014 — To mark its 20th anniversary, Ovarian Cancer Research Fund has awarded a record-breaking $6.9 million in scientific research grants for ovarian cancer and program grants to support gynecologic cancer patients. … Continued

New combination therapy for ovarian cancer shows positive r...

New combination therapy for ovarian cancer shows positive results in Phase I clinical trials

A new combination therapy developed by researchers at the Roswell Park Cancer Institute has showed positive results in 60% of women with recurrent ovarian cancer. To develop the new therapy, researchers took advantage of the fact that ovarian cancer cells have abnormally high a marker called NY-ESO-1 on their surfaces. Researchers gave patients a drug … Continued

OCRF Research Finds New “Chemoimmunotherapy” Ma...

OCRF Research Finds New “Chemoimmunotherapy” May Be New Treatment Option

New research funded by OCRF shows that treatment with the drug decitabine, prior to administration of chemotherapy and a cancer vaccine, yielded clinical benefit for women with recurrent ovarian cancer. This suggests that this combinatorial “chemoimmunotherapy” may provide a new treatment option for patients with this disease. Results of this phase I clinical trial, which … Continued

New Guidelines on Risk, Genetic Counseling & Testing f...

New Guidelines on Risk, Genetic Counseling & Testing for BRCA-related Cancer

(December 30, 2013)   The U.S. Preventive Services Task Force (Task Force) has issued a final recommendation statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-related Cancer in Women. This final recommendation statement applies to women who have no signs or symptoms of a BRCA-related cancer (cancer of the breast, ovary, fallopian tube, or … Continued

High Volume Hospitals and Providers Improve Survival

High Volume Hospitals and Providers Improve Survival

(December 20, 2013)  Researchers have found that for women with advanced-stage ovarian cancer, being treated at a high volume hospital with a high volume provider, leads to improved survival.  The research was published online today in Gynecologic Oncology. Among patients with advanced-stage ovarian cancer, the provider combination of high volume hospital/high volume provider is an … Continued

Partner Member Profile: Hope for Heather

Partner Member Profile: Hope for Heather

Hope for Heather was established in memory of Heather Weeks, a young woman who lost her life to colon cancer but spent her 20s working on behalf of women with ovarian cancer. Heather’s family started the organization in March of 2009. Their original goal was to raise about $1,000 a year for ovarian cancer research; … Continued

Treatment in New Study on Mice with Ovarian Cancer has Posi...

Treatment in New Study on Mice with Ovarian Cancer has Positive Results

A targeted drug delivery system developed at Rutgers University could possibly make ovarian cancer more treatable.  The study results published in Clinical Cancer Research also indicated the new system could increase survival rates in ovarian cancer.  Read the full article here.    

New OCRF Research on Ovarian Cancer Proliferation, Migratio...

New OCRF Research on Ovarian Cancer Proliferation, Migration, and Response to Therapy

Research funded by Ovarian Cancer Research Fund shows that adipose derived stromal cells derived from the human omentum can promote ovarian cancer proliferation, migration, chemoresistance and radiation resistance in-vitro. The research, funded in part through an OCRF grant to senior author Ann Klopp, MD, PhD was published online last week in PLoS One. The researchers hypothesized … Continued

OCRF Research Sheds Light on Ovarian Cancer Origins in BRCA...

OCRF Research Sheds Light on Ovarian Cancer Origins in BRCA Mutation Carriers

A team of current and former OCRF grantees at Brigham and Women’s Hospital, Harvard Medical School and Dana-Farber Cancer Institute has developed genetically engineered mouse models of high-grade serous ovarian cancer that shed light on the pathogenesis of ovarian cancer for BRCA1/2 mutation carriers.  These models, which target the cell of origin (fallopian tube secretory cells) and recreate key genetic … Continued

Supreme Court to Consider Two Birth Control Lawsuits

Supreme Court to Consider Two Birth Control Lawsuits

The Supreme Court recently announced that it will hear two cases involving insurance coverage for birth control. The Alliance weighed in on one of these cases, arguing that oral contraceptives are a proven way to prevent ovarian cancer and should therefore be made available to women who wish to reduce their risk. Our CEO Calaneet … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.